Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
Provided By GlobeNewswire
Last update: Mar 25, 2025
MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its participation in the AD/PD™ 2025 taking place April 1-5 in Vienna.
Read more at globenewswire.com
